onlyTrustedInfo.comonlyTrustedInfo.comonlyTrustedInfo.com
Notification
Font ResizerAa
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
Reading: Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
Share
onlyTrustedInfo.comonlyTrustedInfo.com
Font ResizerAa
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
Search
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
  • Advertise
  • Advertise
© 2025 OnlyTrustedInfo.com . All Rights Reserved.
Finance

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

Last updated: May 11, 2025 8:00 pm
Oliver James
Share
4 Min Read
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
SHARE

A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries‘s (NYSE: TEVA) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result. That was good enough to beat even the very frothy S&P 500‘s (SNPINDEX: ^GSPC) 3.3% gain that trading session.

Contents
Now a buy on cost-cutting and branded productsFuture growth in storeShould you invest $1,000 in Teva Pharmaceutical Industries right now?

Now a buy on cost-cutting and branded products

The person behind the modification was JPMorgan Chase analyst Chris Schott, who pushed up his Teva stock recommendation one notch from neutral to overweight (read: buy). He also bumped his price target higher, from $21 per share to $23. The new level anticipates upside of 28% on the most recent closing stock price.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

According to reports, much of Schott’s new analysis of Teva centers on the cost-cutting measures the company announced recently. In his opinion, the $700 million initiative makes management’s goal of reaching a 30% operating margin by 2027 achievable. At the same time, it should also provide sufficient room for the company to keep its pipeline programs funded.

Past that year, the prognosticator is bullish on Teva’s branded products. In his estimation, drugs like Austedo, Olanzapine, and Duvakitug could drive the company’s growth well higher.

Future growth in store

For the most part, the clutch of analysts tracking Teva are also expecting improvement in key fundamentals.

Collectively, they feel full-year 2025 revenue will tick up by almost 3% this year over 2024 to $17 billion, with per-share net income improving at just under 2%. And although 2026 revenue is forecast to creep less than 1% higher year over year, that per-share net income figure should rise by a robust 9%.

To me, Teva has quite a strong position as a crucial manufacturer of generic drugs. Yet it certainly isn’t neglecting the branded side of its business, which is showing promise these days. I also like how management has assertively cleaned the balance sheet. Therefore, I don’t blame Schott for being more bullish on Teva’s future.

Should you invest $1,000 in Teva Pharmaceutical Industries right now?

Before you buy stock in Teva Pharmaceutical Industries, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teva Pharmaceutical Industries wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $614,911!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $714,958!*

Now, it’s worth noting Stock Advisor’s total average return is 907% — a market-crushing outperformance compared to 163% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of May 12, 2025

JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy.

You Might Also Like

FTC drops Biden-era suit accusing Pepsi of price discrimination

The Top 5 Reasons to Claim Social Security at 62

8 Ways To Stay Safe When Using Mobile Banking Apps

Best Walmart Items To Buy in Each Month of the Year

7 College Majors With the Highest Starting Salaries

Share This Article
Facebook X Copy Link Print
Share
Previous Article Why This Reptile Sounds Like It’s Snoring While Awake Why This Reptile Sounds Like It’s Snoring While Awake
Next Article Foreign overfishing in Senegal fuels migration to Spain, a report finds Foreign overfishing in Senegal fuels migration to Spain, a report finds

Latest News

Atlanta dad’s car now worth K — but he still owes K. Why Ramsey Show hosts say he’s got to take a ‘bath’
Atlanta dad’s car now worth $30K — but he still owes $57K. Why Ramsey Show hosts say he’s got to take a ‘bath’
Finance June 9, 2025
Apple digital feature to make travel easier for domestic fliers
Apple digital feature to make travel easier for domestic fliers
Finance June 9, 2025
A growing number of Fortune 500 companies are pursuing ‘blockchain initiatives’ as crypto goes mainstream
A growing number of Fortune 500 companies are pursuing ‘blockchain initiatives’ as crypto goes mainstream
Finance June 9, 2025
Meet 10 AI trailblazers who are steering their companies into tech’s new age
Meet 10 AI trailblazers who are steering their companies into tech’s new age
Finance June 9, 2025
//
  • About Us
  • Contact US
  • Privacy Policy
onlyTrustedInfo.comonlyTrustedInfo.com
© 2025 OnlyTrustedInfo.com . All Rights Reserved.